JP2016539087A5 - - Google Patents

Download PDF

Info

Publication number
JP2016539087A5
JP2016539087A5 JP2016521266A JP2016521266A JP2016539087A5 JP 2016539087 A5 JP2016539087 A5 JP 2016539087A5 JP 2016521266 A JP2016521266 A JP 2016521266A JP 2016521266 A JP2016521266 A JP 2016521266A JP 2016539087 A5 JP2016539087 A5 JP 2016539087A5
Authority
JP
Japan
Prior art keywords
sap
serum amyloid
agonist
myelofibrosis
agonist according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016521266A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016539087A (ja
JP6636914B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2014/059699 external-priority patent/WO2015054390A1/en
Publication of JP2016539087A publication Critical patent/JP2016539087A/ja
Publication of JP2016539087A5 publication Critical patent/JP2016539087A5/ja
Application granted granted Critical
Publication of JP6636914B2 publication Critical patent/JP6636914B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016521266A 2013-10-08 2014-10-08 線維性癌の治療方法 Active JP6636914B2 (ja)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201361888269P 2013-10-08 2013-10-08
US61/888,269 2013-10-08
US201461992807P 2014-05-13 2014-05-13
US61/992,807 2014-05-13
US201462004836P 2014-05-29 2014-05-29
US201462004828P 2014-05-29 2014-05-29
US62/004,836 2014-05-29
US62/004,828 2014-05-29
PCT/US2014/059699 WO2015054390A1 (en) 2013-10-08 2014-10-08 Methods for treating fibrotic cancers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019229263A Division JP7140739B2 (ja) 2013-10-08 2019-12-19 線維性癌の治療方法

Publications (3)

Publication Number Publication Date
JP2016539087A JP2016539087A (ja) 2016-12-15
JP2016539087A5 true JP2016539087A5 (cg-RX-API-DMAC7.html) 2018-05-31
JP6636914B2 JP6636914B2 (ja) 2020-01-29

Family

ID=52813618

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016521266A Active JP6636914B2 (ja) 2013-10-08 2014-10-08 線維性癌の治療方法
JP2019229263A Expired - Fee Related JP7140739B2 (ja) 2013-10-08 2019-12-19 線維性癌の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019229263A Expired - Fee Related JP7140739B2 (ja) 2013-10-08 2019-12-19 線維性癌の治療方法

Country Status (10)

Country Link
US (2) US11020451B2 (cg-RX-API-DMAC7.html)
EP (2) EP3718558A1 (cg-RX-API-DMAC7.html)
JP (2) JP6636914B2 (cg-RX-API-DMAC7.html)
CN (2) CN114053395A (cg-RX-API-DMAC7.html)
AU (2) AU2014331954B2 (cg-RX-API-DMAC7.html)
CA (1) CA2926418A1 (cg-RX-API-DMAC7.html)
ES (1) ES2784234T3 (cg-RX-API-DMAC7.html)
PL (1) PL3054959T3 (cg-RX-API-DMAC7.html)
RU (2) RU2020111934A (cg-RX-API-DMAC7.html)
WO (1) WO2015054390A1 (cg-RX-API-DMAC7.html)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2020111934A (ru) 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
WO2016168612A1 (en) * 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders
KR102066402B1 (ko) * 2017-12-22 2020-01-15 대화제약 주식회사 이리노테칸 또는 그의 약제학적으로 허용가능한 염을 포함하는 경구투여용 약제학적 조성물
JP7324210B2 (ja) * 2018-01-31 2023-08-09 ティダブリューアイ・バイオテクノロジー・インコーポレイテッド トファシチニブを含む局所製剤
CN112166111A (zh) * 2018-03-28 2021-01-01 布莱德治疗公司 治疗纤维化疾病的方法
CN108715865B (zh) * 2018-05-28 2021-09-21 福建师范大学 用于提高细胞转染效率的试剂组合物
CN119455003A (zh) 2019-02-12 2025-02-18 Ambrx公司 包含抗体-tlr激动剂缀合物的组合物、方法和用途
US20220202803A1 (en) * 2019-04-25 2022-06-30 Clear Creek Bio, Inc. Combination therapies including inhibitors of dihydroorotate dehydrogenase
CN112107556A (zh) * 2019-06-03 2020-12-22 北京大学 一种含砷纳米药物及其制备方法
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
AU2021213469B2 (en) * 2020-01-28 2026-06-04 Raziel Therapeutics Ltd. Compositions for the treatment of angiolipoma
KR102725907B1 (ko) * 2021-11-25 2024-11-04 성균관대학교산학협력단 파크리티닙을 이용한 항암제 내성 암 치료를 위한 병용 요법
EP4680215A1 (en) * 2023-03-17 2026-01-21 MDX Management LLC Compositions and methods for ameliorating adverse effects of therapies

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5270163A (en) 1990-06-11 1993-12-14 University Research Corporation Methods for identifying nucleic acid ligands
ATE318832T1 (de) 1990-06-11 2006-03-15 Gilead Sciences Inc Verfahren zur vervendung von nukleinsäureliganden
CA2135646A1 (en) 1992-05-11 1993-11-25 Kenneth G. Draper Method and reagent for inhibiting viral replication
JPH07509133A (ja) 1992-07-17 1995-10-12 リボザイム・ファーマシューティカルズ・インコーポレイテッド 動物疾患の処置のための方法および剤
US6395713B1 (en) 1997-07-23 2002-05-28 Ribozyme Pharmaceuticals, Inc. Compositions for the delivery of negatively charged molecules
AU8525098A (en) 1997-07-24 1999-02-16 Inex Pharmaceuticals Corporation Liposomal compositions for the delivery of nucleic acid catalysts
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US8946387B2 (en) * 2002-08-14 2015-02-03 Macrogenics, Inc. FcγRIIB specific antibodies and methods of use thereof
US8012472B2 (en) * 2002-12-23 2011-09-06 William Marsh Rice University Compositions and methods for suppressing fibrocytes
US7763256B2 (en) 2002-12-23 2010-07-27 William Marsh Rice University Compositions and methods for suppressing fibrocytes and for detecting fibrocyte differentiation
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
EP1863516A2 (en) * 2005-02-08 2007-12-12 Board of Regents, The University of Texas System Compositions and methods involving mda-7 for the treatment of cancer
GT200600148A (es) * 2005-04-14 2006-11-22 Metodos para el tratamiento y la prevencion de fibrosis
EP2029173B1 (en) * 2006-06-26 2016-07-20 MacroGenics, Inc. Fc riib-specific antibodies and methods of use thereof
JP5220025B2 (ja) * 2006-12-04 2013-06-26 プロメディオール, インコーポレイテッド 線維症疾患を処置するための併用療法
US8497243B2 (en) * 2007-07-06 2013-07-30 Promedior, Inc. Methods and compositions useful in the treatment of mucositis
WO2009009034A2 (en) * 2007-07-06 2009-01-15 Promedior, Inc Methods and compositions useful in the treatment of mucositis
US9884899B2 (en) * 2007-07-06 2018-02-06 Promedior, Inc. Methods for treating fibrosis using CRP antagonists
PT2405929T (pt) * 2009-03-11 2018-07-23 Promedior Inc Métodos de tratamento para distúrbios autoimunes
PT2405928T (pt) 2009-03-11 2017-02-07 Promedior Inc Métodos de tratamento e de diagnóstico para patologias de hipersensibilidade
AU2010232591A1 (en) 2009-04-01 2011-11-03 Promedior, Inc. Pulmonary and nasal delivery of serum amyloid P
UA110323C2 (en) * 2009-06-04 2015-12-25 Promedior Inc Derivative of serum amyloid p and their receipt and application
HUE041034T2 (hu) 2009-06-17 2019-05-28 Promedior Inc SAP-variánsok és alkalmazásuk
WO2013096847A1 (en) 2011-12-21 2013-06-27 Promedior, Inc. Serum amyloid p-antibody fusion proteins
JP2015069119A (ja) 2013-09-30 2015-04-13 パナソニック液晶ディスプレイ株式会社 表示装置
RU2020111934A (ru) 2013-10-08 2020-04-29 Промедиор, Инк. Способы лечения фиброзного рака
WO2016168612A1 (en) 2015-04-15 2016-10-20 Promedior, Inc. Methods for treating myeloproliferative disorders

Similar Documents

Publication Publication Date Title
RU2020111934A (ru) Способы лечения фиброзного рака
JP2018512164A5 (cg-RX-API-DMAC7.html)
US20220054531A1 (en) Treatment of acute myeloid leukemia with hypomethylating agents and 2-o, 3-o desulfated heparinoids
EP3197493B1 (en) Methods of reversing cachexia and prolonging survival comprising administering a gdf15 modulator and an anti-cancer agent
IL278667B1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
US20220313642A1 (en) Tyrosine derivatives and compositions comprising them
WO2015195476A1 (en) Treating myelomas
RU2017139122A (ru) Способы лечения миелопролиферативных нарушений
CN111601609B (zh) 与细胞毒性剂组合的细菌脂多糖的脂质体制剂及其在抗肿瘤疗法中的用途
JP2022153587A (ja) チロシン誘導体及びそれらを含む組成物
WO2012031293A1 (en) Compositions and methods for the treatment of cancer
WO2017152039A1 (en) Protection and delivery of multiple therapeutic proteins
CN1402639A (zh) 药用组合物
CN100409895C (zh) 用于治疗白血病和淋巴瘤的阿普立定组合
JP2009536173A (ja) グルタドン
US20150283237A1 (en) Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer
JP6782932B2 (ja) Npr−aアゴニストの新規用途
JP2022534724A5 (cg-RX-API-DMAC7.html)
WO2020180904A1 (en) Drug delivery for combination of epigenetic modulation and immune checkpoint blockade
CN1845746A (zh) 单独包含去纤苷酸或与其它抗肿瘤剂联合的抗肿瘤制剂
US20230074885A1 (en) Bortezomib-loaded nanoparticles
JP2009292837A (ja) より効能が大きく副作用の少ない癌治療方法
US12233087B2 (en) Palladium hyaluronic acid particles and methods of managing cancer or angiogenic conditions
TW202011946A (zh) 以bet抑制劑及蛋白酶體抑制劑之組合療法
US20210386736A1 (en) Combination therapy for treating cancer